Streamlining ADC Development: Advantage of an All-in-One Solution

[Article Title]

Antibody-drug conjugate (ADC) development requires tightly integrated manufacturing. Streamlined, end-to-end solutions reduce complexity, improve quality, and accelerate time-to-market. By integrating biologics, small molecules and conjugation capabilities, Eurofins CDMO Alphora provides an all-encompassing solution in one location that includes linker-payload production, and mAb development and manufacturing for non-GMP and GMP purposes.

Download the Document

    * denotes a required field

    Please fill out the information below. If you are already registered, and this information will be filled out for you.

  • Please enter your first and last name.

  • Please enter the name of the company or institution you work at.

  • Please enter your mailing address.

  • Please enter the e-mail address you would like to be contacted at.

  • Please enter the phone number you would like to be contacted at.

    • By submitting this form, you consent to American Pharmaceutical Review storing your email address and contact information and transmitting your contact information to the content sponsor. You may request to be removed at any time.